Edoxaban
CAS: 912273-65-5
Ref. 3D-MLB27365
10mg | A consultar | |
25mg | A consultar | |
50mg | A consultar | |
100mg | A consultar | |
250mg | A consultar |
Información del producto
- DU 176b
- Edoxaban tosylate
- Ethanediamide, N-(5-chloro-2-pyridinyl)-N′-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, mono(4-methylbenzenesulfonate)
- Ethanediamide, N<sup>1</sup>-(5-chloro-2-pyridinyl)-N<sup>2</sup>-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, 4-methylbenzenesulfonate (1:1)
- Lixiana
- N-(5-Chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]ethanediamide
- Roteas
- Savaysa
Edoxaban is a nonsteroidal anti-inflammatory drug that is used to prevent blood clots from forming in the atria of the heart. It prevents fibrillation by blocking the action of thromboxane A2, which is a chemical that causes blood vessels to contract and form clots. Edoxaban has been shown to be effective for people with atrial fibrillation who have not responded well to other treatments. Edoxaban has also been shown to reduce natriuretic peptide levels and warfarin levels, as well as bleeding risk in patients who have undergone coronary artery bypass grafting. Edoxaban also reduces the risk of thromboembolism, including heart attack and stroke, when compared with prasugrel or anticoagulant therapy alone.
Propiedades químicas
Consulta técnica sobre: 3D-MLB27365 Edoxaban
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.